Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:approves |
gptkb:U._S._Food_and_Drug_Administration
April 2020 |
| gptkbp:clinical_trial |
Phase 3
improved overall survival improved progression-free survival positive efficacy results second-line treatment third-line treatment ASCENT trial TROPICS-02 trial |
| gptkbp:contraindication |
hypersensitivity to components
severe renal impairment severe liver impairment |
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:frequency |
once every 21 days
|
| gptkbp:healthcare |
gptkb:theorem
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trodelvy
|
| gptkbp:indication |
metastatic breast cancer
|
| gptkbp:ingredients |
sacituzumab govitecan
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
liver function tests
renal function tests blood counts |
| gptkbp:is_used_for |
treatment of triple-negative breast cancer
|
| gptkbp:manager |
intravenous
|
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
|
| gptkbp:market |
available in the United States
available in Canada available in Europe available in Australia |
| gptkbp:marketed_as |
gptkb:2020
|
| gptkbp:pharmacokinetics |
antibody-drug conjugate mechanism
half-life of approximately 13 days |
| gptkbp:population |
gptkb:philosopher
adults |
| gptkbp:price |
high-cost medication
|
| gptkbp:provides_information_on |
included in ASCO guidelines
included in NCCN guidelines |
| gptkbp:receives_funding_from |
collaborative studies with academic institutions
funded by Gilead Sciences |
| gptkbp:research_focus |
biomarker studies
ongoing studies for other cancers real-world evidence studies combination with immunotherapy |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:scholarships |
available for eligible patients
|
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea abdominal pain vomiting decreased appetite diarrhea constipation hair loss neutropenia |
| gptkbp:social_structure |
gptkb:monoclonal_antibody
|
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
Trop-2
|
| gptkbp:treatment |
with chemotherapy
|
| gptkbp:type_of_insurance |
covered by many insurance plans
|
| gptkbp:bfsParent |
gptkb:Immunomedics
|
| gptkbp:bfsLayer |
4
|